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Background: Increasing evidence suggests the bidirectional interplay between parathyroid hormone and
aldosterone as an important mechanism behind the increased risk of cardiovascular damage and bone disease
observed in primary hyperparathyroidism. Our primary object is to assess the efficacy of the mineralocorticoid
receptor-blocker eplerenone to reduce parathyroid hormone secretion in patients with parathyroid hormone
excess.
Methods/design: Overall, 110 adult male and female patients with primary hyperparathyroidism will be randomly
assigned to eplerenone (25 mg once daily for 4 weeks and 4 weeks with 50 mg once daily after dose titration] or
placebo, over eight weeks. Each participant will undergo detailed clinical assessment, including anthropometric
evaluation, 24-h ambulatory arterial blood pressure monitoring, echocardiography, kidney function and detailed
laboratory determination of biomarkers of bone metabolism and cardiovascular disease.
The study comprises the following exploratory endpoints: mean change from baseline to week eight in (1) parathyroid
hormone(1–84) as the primary endpoint and (2) 24-h systolic and diastolic ambulatory blood pressure levels,
NT-pro-BNP, biomarkers of bone metabolism, 24-h urinary protein/albumin excretion and echocardiographic
parameters reflecting systolic and diastolic function as well as cardiac dimensions, as secondary endpoints.
Discussion: In view of the reciprocal interaction between aldosterone and parathyroid hormone and the potentially
ensuing target organ damage, the EPATH trial is designed to determine whether eplerenone, compared to placebo,
will effectively impact on parathyroid hormone secretion and improve cardiovascular, renal and bone health in patients
with primary hyperparathyroidism.
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Parathyroid hormone (PTH) is synthesized and secreted
in the chief cells in the parathyroid gland mainly in re-
sponse to a decreased circulating ionized calcium con-
centration. PTH regulates the calcium und phosphate
homeostasis by activating osteoclasts and osteoblasts,
enhancing intestinal Ca2+ absorption, promoting the
synthesis of active vitamin D in the kidney and increas-
ing active renal Ca2+ reabsorption. Elevation of plasma
Ca2+ concentration in turn decreases PTH secretion by
activating calcium sensing receptors located on chief
cells. A well-balanced calcium homeostasis is crucial for
the regulation of cell signalling, neuromuscular function
and bone metabolism.
Primary hyperparathyroidism (PHPT), the third most
common endocrine disorder, is characterized by excess
PTH secretion, inappropriate with respect to the prevail-
ing circulating ionized calcium concentration [1]. The
identification of PTH receptors within the cardiovascular
(CV) system e.g. in cardiomyocytes, vascular smooth-
muscle and endothelial cells, indicates that PTH excess
may have a potential impact on CV health. In fact, various
observational studies linked PTH excess to a higher risk
of hypertension, left-ventricular hypertrophy, arrhythmia
and metabolic disorders [2-4].
Several observational studies in humans point to an
eminent role of the mineralocorticoid hormone aldoster-
one, produced within the zona glomerulosa (ZG) of the
adrenal gland, in the pathogenesis of CV and renal dis-
ease [5-7]. Relative excess of aldosterone may play an
important role in the genesis of CV damage even in the
absence of primary aldosteronism [8].
Accumulating evidence points to the bidirectional
interplay between PTH and aldosterone as an important
mechanism behind the increased risk of CV damage
observed in PHPT [9,10]. Experimental and clinical data
support the notion that PTH directly stimulates adrenal
steroid secretion by inducing calcium entry in adrenal
ZG cells via binding to PTH/PTH-related protein receptor
(PTH/PTHrP receptor =PTH1R), voltage-gated L-type
calcium channels and by activating various signal trans-
duction pathways [11,12]. The resulting relative aldoster-
one excess triggers increased PTH secretion by facilitating
renal and fecal calcium loss, which in turn aggravates
PTH secretion and CV damage [13].
Given the linkage between aldosterone and PTH,
treatment of either disease (primary aldosteronism and
PHPT) results in positive effects in the other hormone
system. However, studies evaluating the effects of min-
eralocorticoid receptor (MR)-blockade on PTH secre-
tion, CV health and bone metabolism in patients with
PHPT are missing. We therefore suggested the working
hypothesis that in patients with PHPT MR-blockade
with eplerenone decreases iPTH(1–84) levels and exertsbeneficial effects on CV and bone health. To this end we
propose a randomized controlled trial to test this
hypothesis in PHPT patients.
Methods/design
Study design, endpoints and safety
EPATH is a single-center, double-blind, placebo-
controlled, randomized, parallel group trial. Patients
with PHPT diagnosed according to the report of the
3rd International Workshop on Diagnosis of PHPT will
be screened for inclusion into the study [14]. Patients
diagnosed with symptomatic/asymptomatic PHPT will
be consented and screened for eligibility to participate
in the EPATH trial. Overall 110 patients will be rando-
mized to receive eplerenone or placebo in a 1:1 ratio
(55 patients will receive eplerenone and 55 patients will
receive placebo).
The design, conduction and reporting of the EPATH
study adheres to the recommendations of the
CONSORT Statement (http://www.consort-statement.
org/). The study will be performed in accordance with
the Good Clinical Practice (GCP) guidelines and the
Declaration of Helsinki. The study has been approved
(N° 24–032 ex 11/12; EudraCT number: 2011-005683-21)
by the Ethics Committee of the Medical University of
Graz, Austria.
The primary endpoint of the study is to evaluate the
efficacy of eplerenone relative to placebo to reduce PTH
(1–84) concentration, measured by two different labora-
tory methods, in patients with PHPT. Secondary end-
points are the mean changes from baseline after 8-weeks
with eplerenone versus placebo, in the following
measurements: (1) 24-hour systolic and diastolic ambu-
latory blood pressure (ABP) levels; (2) biomakers of
CVD; (3) biomarkers of bone metabolism: osteocalcin,
β-crosslaps, bone alkaline phosphatase and tartrate-
resistant acid phosphatase; (4) 24-h urinary albumin/
protien excretion; and (5) echocardiographic parameters
related to systolic and diastolic function as well as cardiac
dimensions (i.e. left ventricular ejection fraction, E/E´
ratio, left ventricular end-diastolic/systolic pressure/vol-
ume/index and LV posterior wall thickness).
We decided to evaluate the effect of MR-blocker epler-
enone on iPTH(1–84) - the primary outcome – and on
CV and bone health – the secondary outcomes - after
8 weeks because (1) preliminary data from the Graz
Endocrine Causes of Hypertension (GECOH) study sug-
gest that MR-blockade with eplerenone might exert
“rapid” effects on iPTH(1–84) levels [15]; (2) eplerenone
has been shown to significantly lower BP after a few days
of treatment, indicating that this dose may be sufficient
to impact on iPTH(1–84) levels [16]; and (3) in order to
minimize the drop-out number due to eplerenone’s
higher selectivity for the MR, which yields a superior
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pared to spironolactone. In addition, findings from pre-
vious studies suggested that eplerenone appears to
produce more consistent inhibition of some of the non-
genomic effects of aldosterone than spironolactone [17].
Finally, it has been speculated that the extended half-life
of the active metabolites of spironolactone increase the
risk of hyperkalemia and its associated complications
[18]. Conversely, the relatively short half-life of eplere-
none and lack of inactive metabolites may decrease the
risk of hyperkalemia.
Considering the higher prevalence of arterial hyperten-
sion and cardiovascular disease (CVD) in PHPT patients,
which is suggested to result in part from a reciprocal
interaction between aldosterone and PTH, MR-blockade
might be a promising therapeutic strategy to decrease risk
of the development and progression of CVD even in
normotensive patients without materially increasing the
risk of hypotensive side effects [19,20]. In case of severe
side effects related to hypotension, the study drug how-
ever will be discontinued.
The study schema and visit schedule are illustrated in
flow chart in Figure 1. The preliminary screening forFigure 1 Flow chart for the EPATH trial.study eligibility is based on medical records performed
by the study staff at or before the baseline visit. A writ-
ten informed consent will be provided by each eligible
participant, who will be randomly assigned in a double
blind fashion to receive eplerenone 25 mg once daily
(given in the morning) or a matching placebo. If no ad-
verse effects of eplerenone treatment with 25 mg once
daily will be observed after 4 weeks, the dose will be up-
titrated by protocol to the target dose of 50 mg once
daily. This dose titration strategy was chosen to minim-
ise the risk of adverse effects, in particular hyperkalemia.
At week 1 and each subsequent clinic visit, the serum
potassium and creatinie level will be checked. Overall,
the study consists of an 8-week, double-blind, rando-
mized (active) treatment period.
Patients will be requested to be fasting and abstain from
tea, coffee and smoking for overnight at least 12 hours
before applying at the study outpatient. Intake of any
drug should be avoided in the morning before blood col-
lection. Investigations will be done in the morning (8:00
to 12:00). Extreme care will be taken to avoid haemolysis
and prolonged stasis. Laboratory surveillance of serum
electrolytes (potassium, sodium, magnesium and calcium)
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erular filtration rate (GFR) according to the MDRD for-
mula) is required at each study visit. Immediate
suspension of the study drug eplerenone will be disposed
for any measured serum potassium≥ 5.5 mmol/L, and a
down-titration of the study drug will be initiated for any
measured serum potassium≥ 5.0 mmol/L. Furthermore,
the study drug will be discontinued in case of a rise of
serum creatinine≥ 3.0 mg/dL or GFR < 30 mL/min (or
downtitration between GFR 30-49 mL/min), severe ana-
phylactic reactions following or intolerance due to eplere-
none intake, requirement for an open-label use of
eplerenone or potassium sparing diuretics, or formal with-
drawal of the consent.
To minimise the risk of adverse events (e.g. hyperkale-
mia) patients with an eGFR ≤ 50 mL/min and/or a serum
potassium > 5 mmol/L will be excluded from enrollment
into the EPATH Study. Furthermore, the dose of 25 mg
eplerenone once daily is comparably low and will be
titrated to 50 mg once daily, if no adverse effects have
been observed and if well tolerated.
If women of child-bearing age participate in the EPATH
study, pregnancy will be ruled out at the beginning of the
active participation before study enrolment. Further preg-
nancy tests will be performed monthly in our outpatients
(spot urine test), and additionally as a self-test at home
(after thorough education and instruction to perform test
self-tests and after notification per telephone). Female par-
ticipants of child-bearing age will be instructed to perform
contraception throughout the active study period.
Because MR-blocker treatment is currently recom-
mended in all patients with persisting symptoms (NYHA
class II–IV) and an EF <35%, despite treatment with an
ACE inhibitor (or an ARB) and a beta-blocker, special
care was taken to avoid serious side effects such as
hyperkalemia in PHPT patients by (1) excluding those
participants from study participation, who are at higher
risk of developing hyperkalemia; (2) a dose titration
strategy; (3) monitoring of serum electrolytes and renal
function at each study visit [21].
Randomization will be done with assistance of the Insti-
tute of Medical Informatics, Statistics and Documenta-
tion of the Medical University of Graz (http://www.
randomizer.at/). The study staff and participants will be
blinded to treatment assignment for the duration of the
study.
Study medication of either eplerenone (Pfizer Corpor-
ation Austria, Vienna, Austria) or placebo will be packed
in numbered pill boxes (identical in appearance and
packages) according to both a computer generated
randomization list and to international standards, re-
spectively. This will be done by qualified staff at the
pharmacy of the Medical University of Graz, which has
extensive experience with placebo controlled trials.Setting
Eligible study participants will be recruited from the out-
patient clinic of the Department of Internal Medicine,
Division of Endocrinology and Metabolism and Division
of Cardiology, Medical University of Graz, Austria. All
baseline and follow-up visits will be conducted at the De-
partment of Internal Medicine, Division of Endocrinology
and Metabolism and Division of Cardiology and at the
Center of Medical Research of the Medical University of
Graz, Austria.
Inclusion and exclusion criteria
Eligible patients will be men and women of at least
18 years of age with PHPT, who (1) do not meet criteria
for surgical treatment; or (2) in whom surgery is recom-
mended, but not performed because of patient and/or
physician preference; or (3) perceived medical contrain-
dications [22].
Exclusion criteria include (1) 25(OH)D levels <20 ng/dl
(50 nmol/liter); (2) estimated GFR (according to the
MDRD formula) ≤ 50 ml/min; (3) serum potassium
> 5.0 mEq/L (mmol/L) at baseline or > 5.5 mEq/L
(mmol/L) during active study period; (4) side effects
related to hypotension; (5) pregnancy or lactating women;
(6) drug intake as part of another clinical study 4 weeks
before enrolment into the EPATH study and/or during the
active study period; (7) any disease with an estimated life
expectancy below 1 year; (8) chemotherapy or radiation
therapy during the study; (9) intolerance to eplerenone
or any ingredient occurring in eplerenone; (10) severe
acute or chronic liver diseases (Child-Pugh Class C); and
(11) concurrent intake of potassium sparing drugs, e.g.
diuretics (amiloride and triamterene) or CPY3A4-
inhibitors and ongoing potassium supplementation.
Measurements
Anthropometry
Weight and height will be measured wearing no shoes
and light clothes and waist and hip ratio will be deter-
mined according to published recommendations.
Laboratory measurements
All blood samples will be centrifuged within 1 hour after
sampling and will be measured at latest 4 hours after
blood collection. Before analysis or freezing all samples
will be kept at room temperature, except of the samples
for determination of iPTH(1–84) (and plasma aldoster-
one), which will be kept at 4° Celsius. Remaining samples
for long-term storage (whole blood, serum, plasma, urine
and saliva samples) will be kept at −70° to 80° Celsius at
the Biobank Institute of the Medical University of Graz.
Measurement of iPTH(1–84) (pg/mL) will be per-
formed by electrochemiluminiscence immunoassay
“ECLIA” (Elecsys immunoassay analyzer, CobasW, Roche
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assay for determining intact PTH employs a sandwich
test principle in which a biotinylated monoclonal anti-
body reacts with the N-terminal fragment (1–37) and a
monoclonal antibody labeled with a ruthenium complex
reacts with the C-terminal fragment (38–84). The anti-
bodies used in this assay are reactive with epitopes in
the amino acid regions 26–32 and 37–42. Blood for
iPTH(1–84) determination will be collected with stand-
ard EDTA plasma tubes and centrifuged within 5 to
10 minutes.
[Conversion factors of iPTH(1–84) are: pg/mL ×
0.106 = pmol/L and pmol/L × 9.43 = pg/mL, respectively.
Measuring range of the assay: 1.20 (=lower detection
limit) to 5000 pg/mL (=maximum of the master curve);
Reference range: 15–65 pg/mL, interassay coefficient of
variation 3.0-6.5% for PTH 26.7-261 pg/mL).
PTH will be further determined using the electroche-
miluminiscence LIAISON N-tact PTH immunoassay
(DiaSorin Inc., Stillwater, MN, USA).
The measurements of further parameters (25(OH)D,
osteocalcin, β-CrossLaps, bone alkaline phosphatase,
tartrate-resistant acid phosphatase, osteoprotegerin, NT-
pro-BNP) have been previously described in detail [15,23].
All other laboratory measurements will be performed
according to current routine laboratory methods at the
Medical University of Graz.
Measurement of omics-based biomarkers will be per-
formed by Liquid chromatography–mass spectrometry
at the Clinical Institute of Medical and Chemical
Laboratory Diagnostics, Medical University of Graz [24].
Genetic investigations
Genetic analyses (e.g. PCR) will be performed in order
to investigate the impact of e.g. polymorphisms of the
calcium-sensing receptor or of the aldosterone synthase
(CYP11B2) on PTH- and aldosterone secretion.
Genome-wide association analyses will be performed -
within the limits of a hypothesis testing strategy - in
order to examine novel genes/loci implicated in the
regulation of aldosterone and PTH synthesis in concert
with larger studies. Genetic testing will be further
initiated in suspicion of familial form of hyperparathyr-
oidism. Emphasis will be placed upon the genes
associated with familial hypocalciuric hypercalcemia
(FHH), multiple endocrine neoplasia syndrome type I
(MEN1), MEN2, and the hyperparathyroidism jaw-
tumor syndrome.
Echocardiography
Comprehensive echocardiographic analysis of cardiac
function and dimensions will be performed by experi-
enced physicians on echocardiographic device (GE Vivid
3W Pro Echocardiography System, United Kingdom)according to current guidelines of the American Society
of Echocardiography. Tissue Doppler indices will be
recorded at the septal and lateral base of the mitral
annulus.
24-hour systolic/diastolic ambulatory blood pressure
monitoring (ABPM)
Our stuff will be carefully trained to ensure the accuracy
of the ABPM measurement. The ABPM measurements
will be performed in accordance to the established pro-
tocols of the European Society of Hypertension and the
American Association for Medical Instrumentation.
Measurements of 24-hour ABP will be performed by a
validated ABP monitor (Spacelabs 90217; Spacelabs
Healthcare GmbH) and mean 24-hour systolic and dia-
stolic ABP will be recorded. A minimum of 14 readings
during the day and 7 readings overnight will be required
for valid 24-hour ABPM.
Questionnaires
The validated Short Form 36 questionnaire (SF-36)12
will be used as a general estimate for qualtity of life. The
Kansas City Cardiomyopathy Questionnaire is a 23-item,
self-administered instrument, which will be used to
quantify physical function, symptoms (frequency, sever-
ity and recent change), social function, self-efficacy and
knowledge, and quality of life.
Statistical methods
Sample size calculation
Sample size calculation for the primary endpoint iPTH
(1–84) is based on (1) an observed effects of eplerenone
treatment (and adrenalectomy) on iPTH(1–84) levels in
a previously published study [25]; (2) the proven signifi-
cant association between (elevated) PTH levels on risk
of fatal cardiovascular events in humans [3]; and (3) data
derived from patients, which have been managed at the
outpatient clinic of the Division of Endocrinology and
Metabolism at the Medical University of Graz, with pri-
mary hyperparathyroidism.
Based on the observational data from the GECOH
study, MR-blockade (by eplerenone and spironolactone)
in patients with primary aldosteronism was associated
with an approximate 10.0 pg/mL decrease in PTH levels
after a mean follow-up of 12 months [25]. However, two
patients at short-term follow-up of 4 weeks revealed a
similar decrease of PTH levels with MR-blockade com-
pared to long-term follow-up, indicating a rapid effect of
MR-blockade on PTH levels. We are, however, aware
that due to limited evidence regarding the effects of
eplerenone in patients with PHPT, final conclusions can-
not be drawn.
We further evaluated whether an increase of
10.0 pg/mL PTH is translated into a significant higher
Tomaschitz et al. BMC Endocrine Disorders 2012, 12:19 Page 6 of 9
http://www.biomedcentral.com/1472-6823/12/19risk of CV mortality. In the LURIC study comprising
3.300 patients referred to coronary angiography the in-
crement of 10 pg/mL PTH was significantly related to a
4% [Hazard Ratio (95% CI): 1.04 (1.03-1.06) p < 0.001]
higher risk of cardiovascular death [3]. We assumed an
effect size of 10.0 pg/mL, assuring sufficient power to
decrease PTH by eplerenone 25/50 mg once daily. Thus,
for a two-sided alternative-hypothesis with an α of 0.05
and a power (1-β) of 80% we calculated a sample size of
51 study participants per group. To compensate for
drop-outs during the study (estimated to around 10%)
we plan to enrol 55 patients per group.
Outcomes
Outcome variables will be tested for normal distribution
by use of the Kolmogorov-Smirnov test and by further
descriptive statistics. Normally distributed continuous
variables will be given as mean [with standard deviation
(SD)], variables with skewed distribution as median with
interquartile range, and categorical variables as percen-
tages. For parametric procedures all skewed distributed
continuous parameters will be logarithmically trans-
formed (log10). Analysis of covariance, adjusted for the
respective baseline values, will be used to analyze the
continuous primary and secondary outcome variables.
All statistical tests to assess the treatment difference
between eplerenone and placebo will be performed using
a 2-sided hypothesis test at 5% significance level. Data
will be analysed using SPSS 17.0 statistical package
(SPSS, Inc., Chicago, IL, USA).
Discussion
In view of the potential interrelationship between aldos-
terone and PTH in patients with PHPT we hypothesize
that the inhibition of aldosterone mediated effects by
MR-blockade with eplerenone in PHPT patients not
undergoing surgery will (1) result in a decrease of PTH
(1–84) levels, (2) lead to beneficial effects on bone me-
tabolism and (3) exerts beneficial effect on CV health
and kidney function. Thus, the EPATH trial is the first
clinical trial to specifically examine the effects of MR-
blockade on PTH levels, bone, renal and CV health in
patients with PTPH not undergoing surgery.
The “Third International Workshop on Asymptomatic
Primary Hyperparathyroidism” concluded that further
studies are definitely warranted in those patients with
PHPT in whom surgery is not recommended (or indi-
cated) [26]. This is of particular importance considering
that even asymptomatic PHPT is associated with higher
CV morbidity and mortality. To date, little is known
about the mutual interaction between these two hor-
mones and its potential role for target organ damage. In
experimental rat studies combined 5/6 nephrectomy and
parathyroidectomy resulted in decreased aldosteronelevels compared to control rats [27]. Studies in PHPT
patients noted markedly decreased plasma aldosterone
levels and plasma renin activity after parathyroidectomy
[28,29]. In a larger study, Brunaud et al. reported in
patients with PTH excess after parathyroidectomy sig-
nificantly decreased aldosterone and BP levels [30].
Recently, Maniero et al. impressively demonstrated the
expression of the MR in both PTH-secreting adenoma
and in normal parathyroid gland tissue [31]. Interest-
ingly, the MR was predominantly located in the nucleus
of the parathyroid cells, indicating that aldosterone (and
cortisol), participate in a “tonic” regulation of PTH syn-
thesis and secretion. It is one crucial aim of the EPATH
trial to evaluate whether eplerenone inhibits the modula-
tion of PTH secretion and synthesis of aldosterone and
cortisol. In fact, cortisol is also suggested to activate the
MR, particularly in conditions of an increased reactive
oxygen species generation [32]. Moreover, plasma corti-
sol levels increase after PTH infusion and cortisol is sug-
gested to participate in the regulation of PTHrP
expression [33,34]. In addition, we cannot exclude the
possibility that MR blockade can directly inhibit PTH se-
cretion independent of aldosterone and cortisol. Finally,
it is unclear whether eplerenone inhibits some of the
non genomic effects of aldosterone (and cortisol) [17].
Findings from previous studies support the notion that
PTH may stimulate adrenal aldosterone synthesis dir-
ectly. The identification of the PTH/PTH-RP receptor
(PTH1R) in human and rat adrenal cortex binds intact
PTH and the biologically active N-terminal fragment
PTH 1–34 and provides an indication for direct effects
of PTH on ZG cells [35]. Mazzocchi et al. and others
found that PTH and PTH-related protein increase in
human adrenals aldosterone production by binding to
the PTH/PTH-RP receptor [11,12]. In isolated rat ZG
cells exposed to PTH(1–84) and PTH(1–34) Olgaard
et al. observed a 2-fold increased of aldosterone release
resulting from PTH induced Ca2+ionophore-like effects
[36]. Thus, PTH might directly mediate aldosterone pro-
duction by inducing calcium entry in adrenal ZG cells
via binding to PTH/PTH-RP receptors, voltage-gated
L-type calcium channels and by activating various signal
transduction pathways and indirectly by activating the
renin–angiotensin system. Figure 2 summarizes the sug-
gested pathways of an interplay between PTH and the
renin-angiotensin-aldosterone system. With the EPATH
trial we aim to evaluate whether the blockade of aldoster-
one by eplerenone breaks through the stimulating effects
of PTH on aldosterone secretion by decreasing aldoster-
one mediated renal calcium loss and subsequently
enhanced PTH secretion.
Several cross-sectional and prospective studies docu-
mented a strong relationship between both elevated
PTH and aldosterone levels, respectively and arterial
Figure 2 Overview of the bidirectional interplay between aldosterone and PTH. Calcium influx is crucial for activating the synthesis of renin
in juxta glomerular cells and aldosterone in zona glomerulosa cells. Renal renin synthesis is mainly controlled by tubular sodium concentration,
arterial blood pressure and the sympathetic nervous system. PTH is suggested to stimulate renin synthesis by increasing calcium levels in JG cells.
Extracellular potassium, adrenocorticotropic hormone and angiotensin II are major stimulators of aldosterone synthesis in the adrenal glands. Both
factors interact with voltage-gated calcium channels and depolarize the zona glomerulosa cells, which results in elevated intracellular calcium
levels. PTH might directly stimulate aldosterone synthesis by binding to the PTH1R and adrenocorticotropic hormone receptor. In addition, PTH is
suggested to increase sensibilization of angiotensin II, which by itself reduces cellular calcium extrusion through activating Na+/Ca–exchangers in
zona glomerulosa cells. Aldosterone in turn facilitates renal and fecal calcium loss resulting in further PTH secretion.
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[37-40]. Accordingly, one might speculate that the inter-
play between both hormones aggravates BP elevation,
and remodeling of blood vessels in patients with elevated
PTH [41]. This hypothesis would be in line with the
observation of Morfis et al. that aldosterone levels are
strongly related to systolic and diastolic ABPM values.
However, the correlation is less significant if PTH is con-
sidered as confounder [42]. In addition, PTH mediated
intracellular and mitochondrial calcium overload results
in a disturbed redox status in various tissues i.e. in car-
diac myocytes, resulting in increased oxidative stress
[43]. These mechanisms might in part explain the sig-
nificant relationship between circulating aldosterone and
PTH levels and higher risk of left ventricular hyper-
trophy and sudden cardiac death in patients at high CV
risk [3,8,44]. Importantly, aldosterone induced urinary
and fecal Ca2+ and Mg2+ excretion was attenuated by
spironolactone. Furthermore, intake of MR-blockade
resulted in reduced intracellular calcium overload and
improved redox status in peripheral blood mononuclear
cells [13]. The above data suggest that through its cal-
cium wasting properties aldosterone might activate the
PTH-cascade resulting in further target organ damage,
which might be reversed by MR-blockade. In the EPATHstudy we aim to evaluate whether MR-blockers with
eplerenone has effects on 24-h ambulatory arterial blood
pressure, NT-pBNP, kidney function, LV function and
structure in patients with PTH excess.
Increased aldosterone mediated renal calcium loss
might be the key mechanisms for the subsequent devel-
opment of hyperparathyroidism in chronic heart failure
(HF). The majority of studies demonstrated calcium
wasting properties of aldosterone, independent of PTH,
particularly in the setting of dietary salt excess [45,46].
In rats treatment with aldosterone/1% NaCl causes
increased urinary and fecal Ca2+ and Mg2+ excretion,
hypocalcemia, hypomagnesemia and consequently sec-
ondary hyperparathyroidism, as well as increased tissue
calcium concentration. Due to increased PTH activity
bone mineral density and strength were significantly
reduced. Accordingly, HF patients suffering from sec-
ondary aldosteronism and PTH excess are at signifi-
cantly higher risk of orthopedic fractures, in particular
hip fracture, compared to controls [47]. In contrast,
treatment with the MR-blocker spironolactone pre-
vented reduction of bone mineral density in aldoster-
one/salt/loop diuretics treated rats [48]. However,
studies in humans that evaluated the association be-
tween MR-blocker use with fracture risk are rare. One
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associated with total fracture risk (odds ratio: 0.575; 95%
CI: 0.346 to 0.955, p = 0.0324) in men with congestive
HF [49]. Treatment with the MR-blocker spironolactone
was inversely related to fractures in chronic HF males. It
remains (however) to be determined by adequately
designed placebo controlled randomized trials whether
MR-blockade affects bone metabolism and fracture risk
in various risk groups. In the EPATH trial we attempt to
evaluate the effects of aldosterone on bone metabolism
reflected by laboratory markers of bone metabolism in
patients at PTH excess. Considering the above men-
tioned evidence, interventional studies are urgently
needed to evaluate the effects of MR-blockade on bone
mineral density and bone metabolism in chronic HF
patients.
The majority of experimental animal and human
studies identified a clinically relevant interplay between
aldosterone and PTH levels. The bidirectional stimula-
tory effects of PTH and aldosterone may potentiate
the risks of development and progression CV and
bone, kidney disease in patients with PHPT. It has
been suggested that treatment of either disease, aldos-
terone excess and hyperparathyroidism, might posi-
tively affect the CV system by decreasing the activity
of both hormone systems. In view of the potential
interrelationship between aldosterone and PTH in
patients with PHPT the findings from the EPATH
study will facilitate our understanding of the putative
benefits of eplerenone in patients with PTH excess,
and the mechanisms between both hormone systems.
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